Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TACTT2: Efficacy and Safety of AM-101 in the Treatment of Acute Peripheral Tinnitus
2013-005587-26Phase 3Completed
- Sponsor
- Altamira Therapeutics
- Start
- Mar 2014
- Modality
- Small Molecules, Hydrogel Systems → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in tinnitus comparing AM-101 intratympanic injections with Placebo intratympanic injections (2 arms). Primary endpoint: Primary efficacy endpoints. Started Mar 2014; status: completed.
02
Drugs
Keyzilen
03
Conditions
tinnitus
Beyond the preview
Go deeper on 2013-005587-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-005587-26.